JPMORGAN VALUE ADVANTAGE FUND CLASS R2 (JGAQX US) stock market data APIs
37.23
0(0%)
as of June 27, 2025
Try our APIs with
free plan!
JPMORGAN VALUE ADVANTAGE FUND CLASS R2 Financial Data Overview
Price chart is built with
Anychart
Prev. Close
37.23
Open
37.23
High
37.23
Low
37.23
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get JPMORGAN VALUE ADVANTAGE FUND CLASS R2 data using free add-ons & libraries
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get JPMORGAN VALUE ADVANTAGE FUND CLASS R2 End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
JPMORGAN VALUE ADVANTAGE FUND CLASS R2 News
New
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
Delivered Q3 FY2021 Year-to-Date Growth in Reported Revenue of +11% Grew Q3 FY2021 Year-to-Date Reported Operating Profit to 462.5 Billion Yen ($4.0B) and Delivered Competitive Underlying Core Operati...
![FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)](https://eodhd.com/build/assets/fallback-D12a3P93.jpg)
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
VONVENDI [von Willebrand Factor (Recombinant)] is the First and Only Treatment Approved for Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults Living with Severe Type 3 VWD Rec...
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
OSAKA, Japan & CAMBRIDGE, Mass., December 21, 2021--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has received a Complete Response Lette...
Cheplapharm Arzneimittel GmbH -- Moody's changes Cheplapharm's outlook to stable; affirms B2 ratings
Rating Action: Moody's changes Cheplapharm's outlook to stable; affirms B2 ratingsGlobal Credit Research - 20 Dec 2021Paris, December 20, 2021 -- Moody's Investors Service ("Moody's") has today change...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
